Cargando…
Preparation, Optimization and in vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100
Background: Solubility is an important criterion for drug efficacy, independent of the route of administration. It also poses a major challenge for pharmaceutical indus-tries, which are developing new pharmaceutical products, since 40% of the active sub-stances being identified are either insoluble...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691851/ https://www.ncbi.nlm.nih.gov/pubmed/30892168 http://dx.doi.org/10.2174/2211738507666190319124513 |
_version_ | 1783443462582960128 |
---|---|
author | Saharan, P. Bahmani, K. Saharan, S.P. |
author_facet | Saharan, P. Bahmani, K. Saharan, S.P. |
author_sort | Saharan, P. |
collection | PubMed |
description | Background: Solubility is an important criterion for drug efficacy, independent of the route of administration. It also poses a major challenge for pharmaceutical indus-tries, which are developing new pharmaceutical products, since 40% of the active sub-stances being identified are either insoluble or poorly soluble in aqueous media. Objective: The objective of this study was to develop nanoformulation of glipizide drug-loaded nanoparticles providing controlled release formulation. Method: Nanoparticles were prepared by the solvent evaporation method. Eudragit RS100, a nonbiodegradable polymer with varying ratios was used for making the formula-tion. The effect of key formulation variables on the particle size and entrapment efficien-cy and drug loading of nanoparticles were studied by using factorial design. Results: DSC thermograms indicate that glipizide was dispersed in an amorphous state in the polymer. TEM study indicates that the nanoparticles were in spherical shape. The mean diameter was dependent on the presence of the amount of Eudragit RS100 and vis-cosity of the organic phase. The in vitro study showed that the cumulative drug release was from 69.52-81.44% in 10 hrs at pH 6.8 in phosphate buffer respectively. Conclusion: The developed NPs could reduce dose frequency, decrease side effects, and improve patient compliance. Using factorial design, maximum entrapment efficiency with minimum particle size could be achieved with a few experiments. |
format | Online Article Text |
id | pubmed-6691851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-66918512019-09-05 Preparation, Optimization and in vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100 Saharan, P. Bahmani, K. Saharan, S.P. Pharm Nanotechnol Article Background: Solubility is an important criterion for drug efficacy, independent of the route of administration. It also poses a major challenge for pharmaceutical indus-tries, which are developing new pharmaceutical products, since 40% of the active sub-stances being identified are either insoluble or poorly soluble in aqueous media. Objective: The objective of this study was to develop nanoformulation of glipizide drug-loaded nanoparticles providing controlled release formulation. Method: Nanoparticles were prepared by the solvent evaporation method. Eudragit RS100, a nonbiodegradable polymer with varying ratios was used for making the formula-tion. The effect of key formulation variables on the particle size and entrapment efficien-cy and drug loading of nanoparticles were studied by using factorial design. Results: DSC thermograms indicate that glipizide was dispersed in an amorphous state in the polymer. TEM study indicates that the nanoparticles were in spherical shape. The mean diameter was dependent on the presence of the amount of Eudragit RS100 and vis-cosity of the organic phase. The in vitro study showed that the cumulative drug release was from 69.52-81.44% in 10 hrs at pH 6.8 in phosphate buffer respectively. Conclusion: The developed NPs could reduce dose frequency, decrease side effects, and improve patient compliance. Using factorial design, maximum entrapment efficiency with minimum particle size could be achieved with a few experiments. Bentham Science Publishers 2019-09 2019-09 /pmc/articles/PMC6691851/ /pubmed/30892168 http://dx.doi.org/10.2174/2211738507666190319124513 Text en © 2019 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Saharan, P. Bahmani, K. Saharan, S.P. Preparation, Optimization and in vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100 |
title | Preparation, Optimization and in vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100 |
title_full | Preparation, Optimization and in vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100 |
title_fullStr | Preparation, Optimization and in vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100 |
title_full_unstemmed | Preparation, Optimization and in vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100 |
title_short | Preparation, Optimization and in vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100 |
title_sort | preparation, optimization and in vitro evaluation of glipizide nanoparticles integrated with eudragit rs-100 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691851/ https://www.ncbi.nlm.nih.gov/pubmed/30892168 http://dx.doi.org/10.2174/2211738507666190319124513 |
work_keys_str_mv | AT saharanp preparationoptimizationandinvitroevaluationofglipizidenanoparticlesintegratedwitheudragitrs100 AT bahmanik preparationoptimizationandinvitroevaluationofglipizidenanoparticlesintegratedwitheudragitrs100 AT saharansp preparationoptimizationandinvitroevaluationofglipizidenanoparticlesintegratedwitheudragitrs100 |